Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 59

1.

Genetic Hierarchy of Acute Myeloid Leukemia: From Clonal Hematopoiesis to Molecular Residual Disease.

Martignoles JA, Delhommeau F, Hirsch P.

Int J Mol Sci. 2018 Dec 3;19(12). pii: E3850. doi: 10.3390/ijms19123850. Review.

2.

Chronic myelogenous leukemia occurring in a chronic lymphocytic leukemia patient.

Beaud J, Modot T, Delhommeau F, Suner L.

Clin Case Rep. 2018 Jul 4;6(8):1655-1656. doi: 10.1002/ccr3.1572. eCollection 2018 Aug.

3.

Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myélodysplasies.

Drevon L, Marceau A, Maarek O, Cuccuini W, Clappier E, Eclache V, Cluzeau T, Richez V, Berkaoui I, Dimicoli-Salazar S, Bidet A, Vial JP, Park S, Vieira Dos Santos C, Kaphan E, Berthon C, Stamatoullas A, Delhommeau F, Abermil N, Braun T, Sapena R, Lusina D, Renneville A, Adès L, Raynaud S, Fenaux P.

Br J Haematol. 2018 Sep;182(6):843-850. doi: 10.1111/bjh.15490. Epub 2018 Jul 13.

PMID:
30004110
4.

Control in dormancy or eradication of cancer stem cells: Mathematical modeling and stability issues.

Djema W, Bonnet C, Mazenc F, Clairambault J, Fridman E, Hirsch P, Delhommeau F.

J Theor Biol. 2018 Jul 14;449:103-123. doi: 10.1016/j.jtbi.2018.03.038. Epub 2018 Apr 17.

PMID:
29678688
5.

TP53 mutations: the dawn of Shwachman clones.

Donadieu J, Delhommeau F.

Blood. 2018 Jan 25;131(4):376-377. doi: 10.1182/blood-2017-11-815431. No abstract available.

6.

Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors.

Duléry R, Ménard AL, Chantepie S, El-Cheikh J, François S, Delage J, Giannotti F, Ruggeri A, Brissot E, Battipaglia G, Malard F, Belhocine R, Sestili S, Vekhoff A, Delhommeau F, Reman O, Legrand O, Labopin M, Rubio MT, Mohty M.

Biol Blood Marrow Transplant. 2018 May;24(5):1013-1021. doi: 10.1016/j.bbmt.2018.01.005. Epub 2018 Jan 11.

PMID:
29337223
7.

Expression of CD94 by ex vivo-differentiated NK cells correlates with the in vitro and in vivo acquisition of cytotoxic features.

Hasmim M, Khalife N, Zhang Y, Doldur M, Visentin G, Terry S, Giron-Michel J, Tang R, Delhommeau F, Dulphy N, Bourhis JH, Louache F, Chouaib S.

Oncoimmunology. 2017 Jul 18;6(10):e1346763. doi: 10.1080/2162402X.2017.1346763. eCollection 2017.

8.

Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143).

Zhang Y, Saavedra E, Tang R, Gu Y, Lappin P, Trajkovic D, Liu SH, Smeal T, Fantin V, De Botton S, Legrand O, Delhommeau F, Pernasetti F, Louache F.

Sci Rep. 2017 Aug 4;7(1):7305. doi: 10.1038/s41598-017-07848-8.

9.

Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism.

Farge T, Saland E, de Toni F, Aroua N, Hosseini M, Perry R, Bosc C, Sugita M, Stuani L, Fraisse M, Scotland S, Larrue C, Boutzen H, Féliu V, Nicolau-Travers ML, Cassant-Sourdy S, Broin N, David M, Serhan N, Sarry A, Tavitian S, Kaoma T, Vallar L, Iacovoni J, Linares LK, Montersino C, Castellano R, Griessinger E, Collette Y, Duchamp O, Barreira Y, Hirsch P, Palama T, Gales L, Delhommeau F, Garmy-Susini BH, Portais JC, Vergez F, Selak M, Danet-Desnoyers G, Carroll M, Récher C, Sarry JE.

Cancer Discov. 2017 Jul;7(7):716-735. doi: 10.1158/2159-8290.CD-16-0441. Epub 2017 Apr 17.

10.

Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia.

Hirsch P, Tang R, Abermil N, Flandrin P, Moatti H, Favale F, Suner L, Lorre F, Marzac C, Fava F, Mamez AC, Lapusan S, Isnard F, Mohty M, Legrand O, Douay L, Bilhou-Nabera C, Delhommeau F.

Haematologica. 2017 Jul;102(7):1227-1237. doi: 10.3324/haematol.2016.159681. Epub 2017 Mar 16.

11.

Reed Sternberg cell/lymphocyte rosettes in a bone marrow aspirate leading to the diagnosis of Hodgkin lymphoma.

Suner L, Gabignon C, Delhommeau F.

Br J Haematol. 2016 Nov;175(4):557. doi: 10.1111/bjh.14301. Epub 2016 Aug 24. No abstract available.

PMID:
27558759
12.

Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia.

Hirsch P, Zhang Y, Tang R, Joulin V, Boutroux H, Pronier E, Moatti H, Flandrin P, Marzac C, Bories D, Fava F, Mokrani H, Betems A, Lorre F, Favier R, Féger F, Mohty M, Douay L, Legrand O, Bilhou-Nabera C, Louache F, Delhommeau F.

Nat Commun. 2016 Aug 18;7:12475. doi: 10.1038/ncomms12475.

13.

Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia.

Boutzen H, Saland E, Larrue C, de Toni F, Gales L, Castelli FA, Cathebas M, Zaghdoudi S, Stuani L, Kaoma T, Riscal R, Yang G, Hirsch P, David M, De Mas-Mansat V, Delabesse E, Vallar L, Delhommeau F, Jouanin I, Ouerfelli O, Le Cam L, Linares LK, Junot C, Portais JC, Vergez F, Récher C, Sarry JE.

J Exp Med. 2016 Apr 4;213(4):483-97. doi: 10.1084/jem.20150736. Epub 2016 Mar 7.

14.

Clonal history of a cord blood donor cell leukemia with prenatal somatic JAK2 V617F mutation.

Hirsch P, Mamez AC, Belhocine R, Lapusan S, Tang R, Suner L, Bories D, Marzac C, Fava F, Legrand O, Mohty M, Douay L, Delhommeau F.

Leukemia. 2016 Aug;30(8):1756-9. doi: 10.1038/leu.2016.31. Epub 2016 Mar 1. No abstract available.

PMID:
26876594
15.

Effect of mutation order on myeloproliferative neoplasms.

Delhommeau F.

N Engl J Med. 2015 May 7;372(19):1865. doi: 10.1056/NEJMc1503143. No abstract available.

PMID:
25946290
16.

JAK2V617F mRNA metabolism in myeloproliferative neoplasm cell lines.

Nauroy P, Delhommeau F, Baklouti F.

Blood Cancer J. 2014 Jun 27;4:e222. doi: 10.1038/bcj.2014.43. No abstract available.

17.

Interest of cytogenetic and FISH evaluation for prognosis evaluation in 198 patients with acute myeloid leukemia in first complete remission in a single institution.

Hirsch P, Labopin M, Viguié F, Perot C, Isnard F, Mamez AC, Bilhou-Nabera C, Marzac C, Delhommeau F, Lapusan S, Marie JP, Mohty M, Legrand O.

Leuk Res. 2014 Aug;38(8):907-12. doi: 10.1016/j.leukres.2014.05.021. Epub 2014 Jun 4.

PMID:
24957411
18.

TET2 deficiency inhibits mesoderm and hematopoietic differentiation in human embryonic stem cells.

Langlois T, da Costa Reis Monte-Mor B, Lenglet G, Droin N, Marty C, Le Couédic JP, Almire C, Auger N, Mercher T, Delhommeau F, Christensen J, Helin K, Debili N, Fuks F, Bernard OA, Solary E, Vainchenker W, Plo I.

Stem Cells. 2014 Aug;32(8):2084-97. doi: 10.1002/stem.1718.

19.

CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia.

Astori A, Fredly H, Aloysius TA, Bullinger L, Mansat-De Mas V, de la Grange P, Delhommeau F, Hagen KM, Récher C, Dusanter-Fourt I, Knappskog S, Lillehaug JR, Pendino F, Bruserud Ø.

Oncotarget. 2013 Sep;4(9):1438-48.

20.

Applying ecological and evolutionary theory to cancer: a long and winding road.

Thomas F, Fisher D, Fort P, Marie JP, Daoust S, Roche B, Grunau C, Cosseau C, Mitta G, Baghdiguian S, Rousset F, Lassus P, Assenat E, Grégoire D, Missé D, Lorz A, Billy F, Vainchenker W, Delhommeau F, Koscielny S, Itzykson R, Tang R, Fava F, Ballesta A, Lepoutre T, Krasinska L, Dulic V, Raynaud P, Blache P, Quittau-Prevostel C, Vignal E, Trauchessec H, Perthame B, Clairambault J, Volpert V, Solary E, Hibner U, Hochberg ME.

Evol Appl. 2013 Jan;6(1):1-10. doi: 10.1111/eva.12021. Epub 2012 Nov 16.

Supplemental Content

Loading ...
Support Center